Anzeige
Mehr »
Montag, 13.04.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
16:59Allogene Therapeutics Stock Surges 49% On Positive CAR-T Trial Data-
16:48Allogene jumps on analysis of phase 2 data for B-cell lymphoma asset cema-cel5
16:42Regeneron, Telix Enter Strategic Radiopharma Collaboration3
16:38Eilmeldung am Abend: BIONTECH SE ADR zündet Kursrakete!4
16:30Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday2
16:27Revolution Medicines surges 38% on pancreatic cancer breakthrough6
16:26Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda's Entyvio3
16:18Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo5
15:58TD Cowen senkt Kursziel für Caris Life Sciences aufgrund von Bewertungsanpassung1
15:54Baird raises Allogene stock price target to $9 on clinical data2
15:54TD Cowen cuts Caris Life Sciences stock price target on valuation3
15:42TD Cowen reiterates Halozyme stock Buy rating on royalty growth1
15:42Spyre stock maintains Buy rating at Stifel on UC trial data1
15:36Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer150 Phase 1/2 RAINFOL-01 data showed the combination of rinatabart sesutecan (Rina-S) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The...
► Artikel lesen
15:36Revolution Medicines surges on data for pancreatic cancer asset daraxonrasib3
15:35REVOLUTION MEDICINES - Biotech-Aktie zündet nach Studiendaten nächste Rallystufe8
15:34Goldman Sachs bestätigt Rating für Spyre Therapeutics nach positiven Studiendaten1
15:30Goldman Sachs reiterates Early-Stage Biotech on Spyre stock2
15:18Leerink reiterates Spyre stock rating on positive trial data1
15:07Guggenheim reiterates Spyre stock Buy rating after trial results2
Weiter >>